8-K: InMed Shareholders Approve Directors, Auditor, Equity Plan

InMed Pharmaceuticals Inc. shareholders approved the election of five directors, the appointment of CBIZ CPAs P.C. as auditor, and a potential equity issuance plan at its 2025 Annual General and Special Meeting.

Summary

• The 2025 Annual General and Special Meeting of Shareholders was held on December 17, 2025.
• Audited consolidated financial statements for the fiscal year ended June 30, 2025, were presented to shareholders, with no vote taken.
• Five director nominees were elected to the Board: Eric A. Adams (82.03% For), Andrew Hull (82.00% For), Nicole Lemerond (82.11% For), Neil Klompas (82.09% For), and John Bathery (81.94% For).
• CBIZ CPAs P.C. was approved as the independent registered public accounting firm until the 2026 Annual General Meeting, with 78.84% of votes for.
• Shareholders approved the potential issuance of 20% or more of the common shares issued and outstanding as of December 13, 2024, pursuant to the Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., with 65.89% of votes for.
• A total of 993,491 common shares, representing approximately 35.43% of the Company's 2,804,186 issued and outstanding common shares, were represented at the Meeting.

Sentiment

Score: 6

Explanation: The filing reports standard corporate governance approvals, including directors and auditors. The approval of the SEPA provides financial flexibility, which is positive, but the significant 'against' votes for the SEPA and 'withheld' votes for directors indicate some shareholder dissent regarding potential dilution and governance, preventing a higher score.

Positives

• All proposed resolutions, including the election of directors and appointment of the auditor, were approved by shareholders, ensuring continuity in corporate governance.
• Shareholder approval of the Standby Equity Purchase Agreement (SEPA) provides InMed with a flexible mechanism for potential future capital raises, enhancing financial flexibility for its drug development pipeline.

Negatives

• A notable percentage of votes were 'withheld' for director elections, ranging from 17.89% to 18.06%, indicating some level of shareholder dissent.
• A significant percentage of votes (34.11%) were cast 'against' the SEPA share issuance proposal, suggesting shareholder concerns regarding potential dilution.
• Broker non-votes were substantial for the SEPA proposal (840,670), which could indicate a lack of active engagement from some beneficial owners on this key financing item.

Risks

• Forward-looking statements inherently involve numerous risks, uncertainties, and assumptions, many of which are beyond the company's control, and actual results could differ materially.
• The potential issuance of common shares pursuant to the Standby Equity Purchase Agreement (SEPA) could lead to dilution for existing shareholders.
• A complete discussion of the risks and uncertainties facing InMed's business is disclosed in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

Future Outlook

The company's future outlook includes the potential for equity issuances under the approved Standby Equity Purchase Agreement to support its ongoing focus on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, targeting CB1/CB2 receptors.

Management Comments

• InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors.

Industry Context

This filing primarily addresses corporate governance and financing strategies common in the pharmaceutical and biotechnology sectors. The approval of a Standby Equity Purchase Agreement (SEPA) is a typical financing tool for development-stage companies like InMed, which require substantial capital for research and development, especially given the long and costly drug development cycles. The company's focus on small molecule drug candidates targeting CB1/CB2 receptors places it within the specialized area of cannabinoid-based therapeutics or related neurological, ocular, and dermatological indications.

Comparison to Industry Standards

• Shareholder participation of approximately 35.43% at the meeting is relatively low compared to typical averages for larger, more established companies, which often see higher turnout, though it can be common for smaller-cap firms.
• The approval percentages for directors (around 82%) and the auditor (78.84%) are sufficient for passing resolutions but indicate a notable minority of 'withheld' or 'against' votes, which might be higher than the average for uncontested elections in well-performing companies.
• The 34.11% 'against' vote for the SEPA, despite its ultimate approval, highlights significant shareholder concern regarding potential dilution, a common sentiment when such financing instruments are proposed in the capital-intensive biotech industry.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: The approval of the SEPA provides a mechanism for future capital raises, which could support operations and drug development, but also carries the risk of dilution. The election of directors and auditor ensures continued corporate governance.
• **Employees**: Continued operations and potential funding from the SEPA could provide stability for employees by supporting the company's ongoing projects.
• **Creditors**: A potential capital raise via the SEPA could improve the company's liquidity and financial position, potentially reducing credit risk.

Next Steps

• The elected directors will hold office until the 2026 Annual General Meeting of Shareholders or until their successors are elected or appointed.
• The appointed auditor, CBIZ CPAs P.C., will serve until the 2026 Annual General Meeting of Shareholders or until a successor is named.
• The company may proceed with potential equity issuances under the approved Standby Equity Purchase Agreement to secure future funding.

Key Dates

Recommendation

The filing primarily details routine corporate governance matters and the approval of a Standby Equity Purchase Agreement (SEPA). While the SEPA provides a mechanism for future capital, which is crucial for a development-stage pharmaceutical company, it also introduces the risk of dilution. The significant 'against' votes for the SEPA and 'withheld' votes for directors suggest some shareholder apprehension. Without specific updates on drug development milestones or financial performance, the filing does not present a strong catalyst for either a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future developments, particularly regarding the utilization of the SEPA and progress in the drug pipeline.

Keywords

InMed Pharmaceuticals, INM, SEC filing, 8-K, Annual General Meeting, shareholder vote, director election, auditor appointment, Standby Equity Purchase Agreement, SEPA, capital raise, equity issuance, corporate governance, Nasdaq Listing Rules, pharmaceutical, small molecule drug candidates